# EREG

## Overview
Epiregulin (EREG) is a gene that encodes the protein epiregulin, a member of the epidermal growth factor (EGF) family. This protein functions as a ligand for the epidermal growth factor receptor (EGFR) and ERBB4, playing a crucial role in cellular signaling pathways that regulate various physiological processes, including cell proliferation, migration, and differentiation (Freed2017EGFR; Massip‐Copiz2017Epiregulin). Initially expressed as an extracellular transmembrane protein, epiregulin is cleaved to produce a mature soluble form that is involved in normal cellular processes such as wound healing and tissue repair (Massip‐Copiz2017Epiregulin). The protein's interaction with EGFR is characterized by a unique asymmetric dimer structure, which may allow it to engage distinct downstream effectors, potentially acting as a biased agonist (Freed2017EGFR). EREG's expression and activity are significant in both physiological and pathological contexts, including its role in cancer progression and as a predictive biomarker for response to anti-EGFR therapies (KhambataFord2007Expression; Li2023EREG).

## Function
Epiregulin (EREG) is a member of the epidermal growth factor (EGF) family and functions as a ligand for the epidermal growth factor receptor (EGFR). In healthy human cells, EREG is initially expressed as an extracellular transmembrane protein and is cleaved by disintegrins and metalloproteinases (ADAMs) to produce its mature soluble form (Massip‐Copiz2017Epiregulin). EREG is involved in various physiological processes, including cell proliferation, migration, and differentiation. It plays a significant role in normal cellular processes such as wound healing and tissue repair (Massip‐Copiz2017Epiregulin).

In the skin, EREG is produced by keratinocytes and fibroblasts, enhancing keratinocyte proliferation and differentiation, which contributes to skin homeostasis and wound healing (Iwata2021Possible). EREG is also active in the gastrointestinal tract, where it is involved in maintaining normal physiology (Massip‐Copiz2017Epiregulin). Although EREG is upregulated in various pathological conditions, its function in healthy cells primarily involves supporting normal cellular processes and maintaining tissue integrity. The protein's activity is crucial for the regulation of cellular growth and repair mechanisms, highlighting its importance in maintaining healthy tissue function.

## Clinical Significance
Epiregulin (EREG) is implicated in various cancers due to alterations in its expression levels and interactions. In cervical cancer, EREG is upregulated and associated with poor prognosis, particularly in advanced stages. Its overexpression correlates with increased cancer cell proliferation and reduced apoptosis, suggesting a role in cancer cell survival and progression (Li2023EREG). In non-small cell lung cancer (NSCLC), high EREG expression is linked to poor prognosis and aggressive tumor features, such as lymphatic permeation and vascular invasion. It also contributes to therapeutic resistance, particularly in EGFR-mutated and KRAS-mutated cells (Sunaga2024Role; Cheng2021The).

In colorectal cancer, EREG expression serves as a predictive biomarker for response to anti-EGFR therapies like cetuximab. High EREG expression, especially in conjunction with wild-type K-ras status, is associated with improved treatment outcomes (Jonker2013Epiregulin; KhambataFord2007Expression). Conversely, low EREG expression is linked to resistance to these therapies and poorer survival outcomes (Cheng2021The). EREG's role in cancer progression and drug resistance highlights its potential as a therapeutic target and prognostic biomarker across multiple cancer types.

## Interactions
Epiregulin (EREG) interacts with the epidermal growth factor receptor (EGFR) and ERBB4, functioning as a ligand that activates these receptors. EREG induces EGFR dimerization, although it does so more weakly compared to other ligands like epidermal growth factor (EGF). Despite this weaker dimerization, EREG acts as a full agonist of receptor phosphorylation, promoting sustained EGFR activation and autophosphorylation (Freed2017EGFR). EREG's interaction with EGFR involves a unique asymmetric dimer structure, which may allow it to engage a distinct subset of downstream effectors, potentially acting as a biased agonist (Freed2017EGFR).

In the context of pain processing, EREG enhances nociception through the PI3K/AKT/mTOR signaling pathway and increases matrix metalloproteinase-9 (MMP-9) expression. This interaction is crucial for EREG's role in pain modulation, as it potentiates capsaicin-induced calcium influx in sensory neurons (Martin2017Epiregulin). EREG's effects on pain are mediated through EGFR, as inhibitors of EGFR block EREG-induced hypersensitivity, confirming the specificity of this interaction (Martin2017Epiregulin). These interactions highlight EREG's role in cellular signaling pathways that regulate various physiological processes.


## References


[1. (Freed2017EGFR) Daniel M. Freed, Nicholas J. Bessman, Anatoly Kiyatkin, Emanuel Salazar-Cavazos, Patrick O. Byrne, Jason O. Moore, Christopher C. Valley, Kathryn M. Ferguson, Daniel J. Leahy, Diane S. Lidke, and Mark A. Lemmon. Egfr ligands differentially stabilize receptor dimers to specify signaling kinetics. Cell, 171(3):683-695.e18, October 2017. URL: http://dx.doi.org/10.1016/j.cell.2017.09.017, doi:10.1016/j.cell.2017.09.017. This article has 276 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.cell.2017.09.017)

[2. (Jonker2013Epiregulin) D J Jonker, C S Karapetis, C Harbison, C J O’Callaghan, D Tu, R J Simes, D P Malone, C Langer, N Tebbutt, T J Price, J Shapiro, L L Siu, R P W Wong, G Bjarnason, M J Moore, J R Zalcberg, and S Khambata-Ford. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. British Journal of Cancer, 110(3):648–655, December 2013. URL: http://dx.doi.org/10.1038/bjc.2013.753, doi:10.1038/bjc.2013.753. This article has 61 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/bjc.2013.753)

[3. (Li2023EREG) Tianye Li, Ruijing Feng, Bingxin Chen, and Jianwei Zhou. Ereg is a risk factor for the prognosis of patients with cervical cancer. Frontiers in Medicine, March 2023. URL: http://dx.doi.org/10.3389/fmed.2023.1161835, doi:10.3389/fmed.2023.1161835. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmed.2023.1161835)

[4. (Iwata2021Possible) Hiroaki Iwata, Naoya Haga, and Hideyuki Ujiie. Possible role of epiregulin from dermal fibroblasts in the keratinocyte hyperproliferation of psoriasis. The Journal of Dermatology, 48(9):1433–1438, June 2021. URL: http://dx.doi.org/10.1111/1346-8138.16003, doi:10.1111/1346-8138.16003. This article has 6 citations.](https://doi.org/10.1111/1346-8138.16003)

[5. (Massip‐Copiz2017Epiregulin) Macarena Massip‐Copiz, Mariángeles Clauzure, Ángel G. Valdivieso, and Tomás A. Santa‐Coloma. Epiregulin (ereg) is upregulated through an il‐1β autocrine loop in caco‐2 epithelial cells with reduced cftr function. Journal of Cellular Biochemistry, 119(3):2911–2922, November 2017. URL: http://dx.doi.org/10.1002/jcb.26483, doi:10.1002/jcb.26483. This article has 22 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcb.26483)

[6. (Cheng2021The) Wan-Li Cheng, Po-Hao Feng, Kang-Yun Lee, Kuan-Yuan Chen, Wei-Lun Sun, Nguyen Van Hiep, Ching-Shan Luo, and Sheng-Ming Wu. The role of ereg/egfr pathway in tumor progression. International Journal of Molecular Sciences, 22(23):12828, November 2021. URL: http://dx.doi.org/10.3390/ijms222312828, doi:10.3390/ijms222312828. This article has 87 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms222312828)

[7. (Martin2017Epiregulin) Loren J. Martin, Shad B. Smith, Arkady Khoutorsky, Claire A. Magnussen, Alexander Samoshkin, Robert E. Sorge, Chulmin Cho, Noosha Yosefpour, Sivaani Sivaselvachandran, Sarasa Tohyama, Tiffany Cole, Thang M. Khuong, Ellen Mir, Dustin G. Gibson, Jeffrey S. Wieskopf, Susana G. Sotocinal, Jean Sebastien Austin, Carolina B. Meloto, Joseph H. Gitt, Christos Gkogkas, Nahum Sonenberg, Joel D. Greenspan, Roger B. Fillingim, Richard Ohrbach, Gary D. Slade, Charles Knott, Ronald Dubner, Andrea G. Nackley, Alfredo Ribeiro-da-Silva, G. Gregory Neely, William Maixner, Dmitri V. Zaykin, Jeffrey S. Mogil, and Luda Diatchenko. Epiregulin and egfr interactions are involved in pain processing. Journal of Clinical Investigation, 127(9):3353–3366, August 2017. URL: http://dx.doi.org/10.1172/jci87406, doi:10.1172/jci87406. This article has 85 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci87406)

[8. (Sunaga2024Role) Noriaki Sunaga, Yosuke Miura, Tomomi Masuda, and Reiko Sakurai. Role of epiregulin in lung tumorigenesis and therapeutic resistance. Cancers, 16(4):710, February 2024. URL: http://dx.doi.org/10.3390/cancers16040710, doi:10.3390/cancers16040710. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers16040710)

[9. (KhambataFord2007Expression) Shirin Khambata-Ford, Christopher R. Garrett, Neal J. Meropol, Mark Basik, Christopher T. Harbison, Shujian Wu, Tai W. Wong, Xin Huang, Chris H. Takimoto, Andrew K. Godwin, Benjamin R. Tan, Smitha S. Krishnamurthi, Howard A. Burris, Elizabeth A. Poplin, Manuel Hidalgo, Jose Baselga, Edwin A. Clark, and David J. Mauro. Expression of epiregulin and amphiregulin and k-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. Journal of Clinical Oncology, 25(22):3230–3237, August 2007. URL: http://dx.doi.org/10.1200/jco.2006.10.5437, doi:10.1200/jco.2006.10.5437. This article has 932 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1200/jco.2006.10.5437)